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Current approaches for identifying synergistic tar-
gets use cell culture models to see if the combined
effect of clinically available drugs is better than pre-
dicted by their individual efficacy. New techniques
are needed to systematically and rationally identify
targets and pathways that may be synergistic
targets. Here, we created a tool to screen and identify
molecular targets that may synergize with new inhib-
itors of target of rapamycin (TOR), a conserved
protein that is a major integrator of cell proliferation
signals in the nutrient-signaling pathway. Although
clinical results fromTORcomplex 1 (TORC1)-specific
inhibition using rapamycin analogs have been disap-
pointing, trials using inhibitors that also target
TORC2 have been promising. To understand this
increased therapeutic efficacy and to discover sec-
ondary targets for combination therapy, we engi-
neered Tor2 in S. cerevisiae to accept an orthogonal
inhibitor. We used this tool to create a chemical epis-
tasisminiarray profile (ChE-MAP) bymeasuring inter-
actions between the chemically inhibited Tor2 kinase
and a diverse library of deletion mutants. The ChE-
MAP identified known TOR components and distin-
guished between TORC1- and TORC2-dependent
functions. The results showed a TORC2-specific
interaction with the pentose phosphate pathway, a
previously unappreciated TORC2 function that sug-
gests a role for the complex in balancing the high en-
ergy demand required for ribosome biogenesis.INTRODUCTION
Kinase signaling networks are primary regulators of cell growth
and division. Improper signaling caused by mutations to kinasesCell Reis a major driver of cancer progression (Greenman et al., 2007;
The Cancer Genome Atlas Research Network, 2013; Wood
et al., 2007). The success of targeting single kinases has been
mixed due to rapidly emerging drug resistance and significant
toxicity that limits the use of several of these agents to doses
that do not block cancer growth (Boss et al., 2009; Greenman
et al., 2007; Haura et al., 2010; The Cancer Genome Atlas
Research Network, 2013; Wood et al., 2007). In contrast, the
vast majority of clinically available therapeutics have multiple
targets (Knight et al., 2010; Mestres et al., 2009). Many of these
off-targets contribute to the therapeutic efficacy of these drugs,
but also increase their toxicity and side effects. Many preclinical
and clinical studies have searched empirically for synergistic
activities of kinase-targeted therapies, but systematic studies
are far less common. In this study, we endeavored to systemat-
ically study synergistic interactions with target of rapamycin
(TOR) kinase activity.
TOR is a primary integrator of proliferative signals, and aber-
rant signaling by this kinase contributes to cancer (Casadio
et al., 1999; Inoki et al., 2005; Kaeberlein et al., 2005; Martin
and Hall, 2005; Tee and Blenis, 2005; Tischmeyer et al., 2003).
As clinical use of selective inhibitors of TOR complex 1
(TORC1; rapamycin and its derivatives, rapalogs) becomes
more widespread in cancer treatment and ATP-competitive
inhibitors of both TORC1 and TORC2 (including BEZ235, INK-
128/MLN0128, KU-0063794, and WYE-354) reach the clinic,
the search for secondary targets to use in combination therapy
will gain urgency.
In addition to the clinical utility of an efficient method to find
secondary targets to use in combination with TOR inhibitors,
we were motivated by the fundamental lack of understanding
of TORC2 biology resulting from the lack of pharmacology to
selectively inhibit this complex. Although prior studies have
identified roles for TORC2 in cytoskeletal reorganization, sphin-
golipid biosynthesis, and ribosome biogenesis (Beeler et al.,
1998; Breslow et al., 2008; Helliwell et al., 1998b; Roelants
et al., 2004; Schmidt et al., 1997; Zinzalla et al., 2011), it has
been impossible to monitor these interactions on the rapid time-
scales that are possible with drug inhibition. It has also beenports 5, 1725–1736, December 26, 2013 ª2013 The Authors 1725
impossible to specifically trace the function of these interactions
to the ‘‘kinase activity’’ of TORC2.
Although selective pharmacological inhibition of TORC2 in
mammals is not easily achieved since both TOR complexes
share the same kinase, S. cerevisiae has two distinct kinase
genes that can be independently inhibited: TOR1 and TOR2.
TORC1 can contain TOR1 or TOR2 and is rapamycin sensitive.
TORC2 contains only TOR2 and is rapamycin insensitive (Loe-
with et al., 2002). The presence of distinct TOR kinases in yeast
is a key advantage that enables independent modification of the
active site of Tor2 using chemical genetics to generate a selec-
tive inhibitor for a modified allele of TORC2 (Bishop et al., 2000).
To study the selective pharmacology of TORC2 inhibition, we
engineered an allele of TOR2, analog-sensitive TOR2 (AS-
TOR2), to accept an orthogonal kinase inhibitor that would not
inhibit TORC1. To generate an unbiased map of the signaling
network that TORC2 participates in, and to furnish a list of inter-
esting secondary targets for combination therapy, we deter-
mined chemical-genetic interactions between the TORC2 kinase
and1,000 nonessential genes in S. cerevisiae. For comparison,
we generated a chemical-genetic interaction data set using the
TORC1 inhibitor rapamycin. This approach enabled independent
investigation of genetic interactions arising from the catalytic
activity of either TOR complex.
Typically, genetic interactions report on how the function of
one gene depends on the function of another. Negative inter-
actions occur when two mutations cause the resulting double
mutant to grow worse than expected relative to the growth
rate of the two single mutants, and indicate that the two genes
function in redundant or compensatory pathways. Positive
interactions occur when the double mutant grows better than
expected based on the phenotypes of the two single mutants,
suggesting the two genes function in the same complex or in a
linear pathway (Beltrao et al., 2010; Collins et al., 2007; Fiedler
et al., 2009; Kelley and Ideker, 2005; Roguev et al., 2008; Ryan
et al., 2012; Schuldiner et al., 2005; Tong et al., 2004). Retaining
this framework for interpretation, we developed a tool for
analyzing the dose-dependent effect of selective inhibitors,
termed chemical epistasis mini-array profile (ChE-MAP).
ChE-MAP is a pharmacological extension of the powerful
E-MAP technology, which typically relies on the growth pheno-
type of double-deletion mutants (Collins et al., 2010, 2006;
Schuldiner et al., 2006) and enables dose-dependent kinase-
gene interactions to be identified. The gene interactions are
akin to an allelic series ranging from hypomorphic (low-dose
drug treatment) to severe loss of function (high-dose drug treat-
ment). This approach contrasts with previous E-MAPs that used
drugs to either induce or modify the phenotype in double-
deletion mutants (Bandyopadhyay et al., 2010). Instead, inter-
actions in our ChE-MAP result from the combined effects of a
single-deletion mutant and chemical inhibition of TOR kinase
activity. This analysis enables characterization of the TOR
signaling network due to rapid inactivation of either TORC1 or
TORC2.
We use the ChE-MAP approach to provide an unbiased view
of interactions with the catalytic function of the two TOR
complexes. The results recapitulate known regulatory relation-
ships between TORC2 and sphingolipid biosynthesis. Statistical1726 Cell Reports 5, 1725–1736, December 26, 2013 ª2013 The Autanalysis revealed enrichment in metabolic processes, and
analysis of metabolic pathways revealed an interaction network
signature suggesting the involvement of TORC2 in regulating the
pentose phosphate pathway (PPP). Further study showed that
levels of key metabolites in the PPP decreased in response to
TORC2 inhibition, but not TORC1 inhibition, suggesting a
specific and previously unappreciated role for TORC2 in regu-
lating cellular ribosides.
RESULTS AND DISCUSSION
A Chemical-Genetic Tool for Studying TORC2
AS kinases contain an active-site mutation, termed the gate-
keeper, that allows selective inhibition with a compound that is
too bulky to fit into the active site of wild-type (WT) kinases
(Bishop et al., 2000). This residue is typically a branched-chain
amino acid in the hydrophobic affinity pocket within the active
site of the kinase (Buzko andShokat, 2002).Mutation to a smaller
residue permits binding of the bulky inhibitor.
Based on the homology of mammalian TOR (mTOR) to phos-
phatidylinositol 3-kinase g (PI3Kg), we performed a structure-
based alignment to identify the gatekeeper residue (I2237) of
H. sapiens mTOR (Figure 1A). Insertion of the mTOR inhibitor
BEZ235 into the active site guided by the affinity of the backbone
carbonyl of V2227 to the quinoline nitrogen (the most common
mode of kinase inhibitor binding) shows a steric clash with the
hydrophobic pocket that is exacerbated in the presence of other
branched-chain aliphatic residues, such as leucine (shown). This
binding mode was confirmed in the recently published structure
of mTOR bound to the structurally related inhibitor Torin2 (Yang
et al., 2013). In contrast, the reported WT Tor1/2 inhibitor in
yeast, QL-IX-55 (Liu et al., 2012), which contains a smaller
moiety, 2-aminopyridine, in place of the quinoline moiety, shows
no steric clash. We reasoned that we could mutate the gate-
keeper to a smaller residue in order to make space in the hydro-
phobic affinity pocket to accommodate a larger inhibitor. We
then performed a sequence alignment to identify the conserved
leucine gatekeeper in S. cerevisiae Tor2 (Figure 1B). The gate-
keeper residue of S. cerevisiae Tor2 was identified as L2178,
mutated to alanine, and genomically integrated into the TOR2 lo-
cus, yielding cells containing AS-TOR2.
Since Tor2 kinase activity is essential in S. cerevisiae, replace-
ment of Tor2 with a mutant that supports viability indicates that
the AS-TOR2 allele is catalytically active. The nearly equivalent
growth rates of WT and AS alleles in YPD (Figure S1A) indicate
that the AS-TOR2 cells have a functional kinase.
Screening of the mutant kinase against a panel of 40 ATP
analogs and kinase inhibitors (Figure S1B) revealed that the
AS-TOR2 allele was selectively inhibited by a single agent,
BEZ235, whereas the growth of WT-TOR2 was relatively insen-
sitive to this compound (Figure 1C). Although typical chemical
scaffolds for inhibition of AS kinases based on a pyrazolo-pyrim-
idine scaffold (Bishop et al., 2000), or compounds designed to
target the gatekeeper residue of lipid kinases (Alaimo et al.,
2005) showed no activity toward AS-TOR2 (Figure S1C),
BEZ235 (but not other compounds) also inhibited AS-MEC1,
suggesting that this compoundmay be a novel and general scaf-
fold for inhibiting AS kinases in the PIKK family.hors
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Figure 1. Modeling and Characterization of the AS-TOR2 Allele
(A) A homology model of mTOR based on the structure of PI3Kg is shown with the gatekeeper residue in gray. The known S. cerevisiae TOR1/TOR2 inhibitors
QL-IX-55 (purple) and BEZ235 (magenta) are oriented based on a typical hydrogen-bonding interaction with the backbone carbonyl of valine in the active site at
van derWaals distances away from other residues that form the ATP-binding pocket. The isoleucine gatekeeper clash with BEZ235 is exacerbated bymutation to
leucine and alleviated by mutation to alanine. The smaller QL-IX-55 does not sense this residue.
(B) Sequence alignment shows that the gatekeeper residue (in purple) is isoleucine in mTOR and leucine in all other cases. The active site is highly conserved.
(C) EC50 of AS-TOR2 and WT-TOR2 growing in culture. AS-TOR2 is significantly more sensitive to BEZ235 than is WT-TOR2.
(D) AS-TOR2 has a growth rate identical to that of WT-TOR2 when grown on YPD. At higher doses (1 mMBEZ235), growth of AS-TOR2 is inhibited, whereas WT-
TOR2 is unaffected. Growth of WT-TOR2 begins to be affected at 2 mM BEZ235.
(E) In vivo phosphorylation of Ypk1 by TORC2 inWT-TOR2- and AS-TOR2-containing cells. AS-TOR2 is significantly more sensitive to BEZ235 than is WT-TOR2.
(F) IC50 values show that BEZ235 does not inhibit TORC1, AS-TOR2 does not play a significant role in the catalytic function of TORC1, and the compound
selectively inhibits AS-TOR2 in TORC2 over WT-TOR2. The in vitro values correspond well to in vivo results, which are typically less sensitive due to high
concentrations of ATP and the poor cell-wall permeability of yeast.
See also Figures S1, S2, and Table S5.Although BEZ235 is a potent mTOR inhibitor in mammals
(Maira et al., 2008), it only has activity toward WT yeast at high
concentrations (Figures 1C and 1D), and mutation of Tor2 to
the mTOR gatekeeper (isoleucine) does not confer sensitivity
to the drug (Figure S2). This is likely due to slightly different
positioning of the hinge loop in the mTOR kinase that pulls the
quinolone moiety farther away from the hydrophobic pocket
containing the gatekeeper residue.
In order to characterize the specificity of BEZ235 for AS-
TOR2, we investigated potential off-target effects of the
compound on kinases in the same family. We ruled out off-target
effects of BEZ235 on essential kinases (Mss4 and Pik1) since
these would have resulted in growth inhibition of WT cells. ToCell Retest whether BEZ235 was targeting the PI3K ortholog Vps34,
we made Vps34 conditionally essential in a DTOR1 background
and observed no growth inhibition by BEZ235 (Figure S2). The
compound also showed no activity toward WT-TOR1 or WT-
TOR2 alleles when perturbed at high temperature or pharmaco-
logically using rapamycin (Figure S2).
To test the selectivity of BEZ235 for AS-TOR2, we measured
the cellular EC50 of AS-TOR2 in liquid culture. The EC50 of
AS-TOR2 is 189 nM compared with an EC50 of 1,035 nM for
WT-TOR2 (Figure 1C). Since we planned to do many experi-
ments on agar plates, we also performed a dose series from
0.1 to 2.0 mM BEZ235 (Figure 1D). The results show potent inhi-
bition of the AS-TOR2 strain and only a slight growth defect inports 5, 1725–1736, December 26, 2013 ª2013 The Authors 1727
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Figure 2. Chemical Epistasis Mapping of TORC1 and TORC2
(A) TOR1 exists only as a member of TORC1. TOR2 may exist as a member of either TORC1 or TORC2. Rapamycin selectively inhibits TORC1. BEZ235 is
selective for the AS-TOR2 allele. Chemical-genetic interactions behave as traditional double-deletion mutants. For interacting genes, a directional shift between
the DMSO control and the (high) drug screen should occur. Dose-dependent positive interactions occur between genes in linear pathways, and dose-dependent
negative interactions occur between genes in parallel pathways.
(B) TOR mutant strains were mated to a library of 1,000 nonessential single-deletion mutants. The resulting double mutants were grown on plates containing
DMSO or increasing concentrations of rapamycin or BEZ235.
(legend continued on next page)
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WT-TOR2 cells at the highest concentration. In order to verify
that these effects were due to selective inhibition of TORC2
in vivo, we compared the phosphorylation of the well-character-
ized TORC2 substrate, Ypk1, in WT-TOR2 cells and AS-TOR2
cells. Although phospho-Ypk1 does not show significant inhibi-
tion until 4 mM BEZ235 in WT cells, it does show significant inhi-
bition at 0.25 mM in AS-TOR2 cells (Figure 1E).
To assess whether this sensitivity was due to the Tor2 kinase,
we performed in vitro kinase assays using TORC2 purified (with
hemagglutinin (HA)-tagged Tsc11, a TORC2-specific com-
ponent) from cells containing AS-TOR2 or WT-TOR2. The kinase
assay shows that the IC50 of BEZ235 for TORC2 is 50 nM,
whereas the IC50 for WT is 111 nM (Figures 1F and S2). The
potency was measured at 100 mM ATP. Since the mutation
commonly increases the KM for ATP (Zhang and Shokat, 2007),
the decrease in competition with ATP would further enhance
the efficacy of BEZ235 in cells.
Two potentially complicating factors in our analysis of TORC2
function through inhibition of AS-TOR2 were (1) the presence of
Tor2 in TORC1 (Loewith et al., 2002) and (2) the possibility that
BEZ235 might simply inhibit TORC1 in the presence of a slightly
weaker AS-TOR2 allele. To test whether TOR2 is amajor contrib-
utor to the activity of TORC1, and whether BEZ235 inhibited
TORC1, we purified TORC1 from AS-TOR2 and WT-TOR2 cells.
We found that the IC50 of BEZ235 for TORC1 purified from WT
cells is 423 nM. This IC50 is too weak to account for the potent
growth inhibition of AS-TOR2, since there is at least a 5-fold
and sometimes a 100-fold shift in potency from in vitro IC50 to
in vivo EC50 due to cellular competition with ATP and the poor
permeability of the cell wall in yeast. This indicates that
BEZ235 does not inhibit TORC1, particularly at the concentra-
tions used in this study. Furthermore, the IC50 of BEZ235 for
TORC1 purified from AS-TOR2-containing cells (432 nM) indi-
cates that there is no significant inhibition of any AS-TOR2 that
may participate in TORC1 (Figures 1F and S2).
Finally, to assess whether BEZ235 inhibits TORC1 in vivo,
we compared the phosphorylation of the TORC1 substrate
Sch9 at T737 (Urban et al., 2007) in cells containing both
WT-TOR2 and AS-TOR2. We did not observe a significant
difference in Sch9 phosphorylation between the two strains,
indicating that BEZ235 does not inhibit TORC1 (Figure S2),
whereas rapamycin did block Sch9 phosphorylation equivalently
in both WT-TOR2 and AS-TOR2 cells.
To characterize the genetic interactions resulting from selec-
tive inhibition of TORC1, we performed screens with the WT(C) ChE-MAP for rapamycin-treated and BEZ235-treated data sets sorted accor
teractions (S scores) are reported by yellow or blue squares, respectively. Inset:
many strains were very sick at the highest concentration of BEZ235 and were re
(D) Experimental data sets (WT-TOR2+rapa and AS-TOR2+BEZ) and control data
of total interactions in the data set above DSR j2.6j. Positive interactions are in y
their intended targets and generate few off-target interactions.
(E) A scatterplot of DS score versus S score illustrates the specific effect of BEZ2
around 0. AS-TOR2 (blue) is strongly affected and shows a direct relationship be
(F) Number of dose-dependent genetic interactions above DSR j2.6j in each set;
with an overlap of ten.
(G) Network illustrating genes that hit both TORC1 and AS-TOR2 above the spe
negative interactions with the indicated complex.
See also Figures S2, S3, and Tables S1, S2, S3, and S5.
Cell Reallele in the presence of rapamycin and with the AS-TOR2 allele
in the presence of BEZ235. These data sets shed light on the
distinct signaling networks of TORC1 and TORC2 and provide
an unbiased and selective investigation of genetic interactions
with TORC2 kinase activity (Figure 2A).
A Global Map of Genetic Interactions with the TOR2
Kinase
To systematically investigate synergistic interactions with
TORC1 and TORC2, we combined our chemical-genetic tool
with high-throughput yeast genetics to quantitatively assess
the strength of synergistic interactions against a broad set of
deleted genes. We systematically crossed either WT-TOR2 or
the AS-TOR2 allele with a library of1,000 nonessential deletion
mutants and selected for haploid double-mutant strains
(Figure 2B). By growing strains on synthetic complete media
containing either DMSO or increasing concentrations of rapamy-
cin or BEZ235, we were able to measure dose-dependent
growth phenotypes of mutant yeast colonies and use these
phenotypes to compute individual genetic interaction scores.
These screens were done in tandem with many other queries
(Table S1) to ensure the robust statistics that are required for
calculation of S scores (Collins et al., 2006, 2010; Schuldiner
et al., 2006).
To evaluate the strength of the chemical-genetic interaction
with either TOR complex, we computed S scores for all observed
strains. An S score is a quantitative assessment of the strength
and reproducibility of the interaction between two alleles (Collins
et al., 2006, 2010). For interactions that showed a consistent and
directional trend in correlating with drug dose, we calculated a
difference score DS (DS = High Drug – DMSO). Since DS is a
close analog to S score, and S = 2.6 has been used as a cutoff
for significance in published literature (Fiedler et al., 2009), we
chose DSR j2.6j as a cutoff for significance in our analysis.
Three of these data sets are experimental controls for off-
target effects of the compounds (Figure 2B). WT-TOR2 and
AS-TOR2 cells were treated with the same concentrations of
BEZ235, and rapamycin-resistant (rr) alleles (Cafferkey et al.,
1993; Heitman et al., 1991; Helliwell et al., 1994) of TOR1 and
TOR2 (S1972I-TOR1 and S1975I-TOR2) were treated with rapa-
mycin. The limited number of genes that showed dose-depen-
dent interactions with the drug-resistant alleles were filtered
from the experimental data sets. The two experimental data
sets reveal dose-dependent genetic interactions between spe-
cific yeast genes and rapamycin or BEZ235 (Figure 2C; Tableding to DS score. The strengths of positive and negative chemical-genetic in-
top hits from each set. The AS-TOR2 data set is significantly smaller because
moved during quality filtering.
sets (rr-TOR1+rapa, rr-TOR2+rapa, andWT-TOR2+BEZ) are shown by percent
ellow, negative interactions are blue. Rapamycin and BEZ235 are selective for
35 on AS-TOR2. WT-TOR2 (red) is unaffected by the compound and clusters
tween DS score and S score at 1 mM BEZ235.
104 interactions were recorded for rapamycin and 134 were recorded for BEZ,
cified threshold. Nodes and edges are colored yellow for positive or blue for
ports 5, 1725–1736, December 26, 2013 ª2013 The Authors 1729
S2). The examined library of yeast genes included genes from
all functional categories, including regulatory proteins, signaling
machinery, cell-cycle regulators, and metabolic enzymes
(Table S2).
Characteristic Dose-Dependent ChE-MAP Interactions
Analysis of ChE-MAPs generated with WT cells mated to dele-
tion mutants and grown on 0, 0.25, or 1 mM of BEZ235 shows
that the compound is selective for the AS allele, with few off-
target effects (Figure 2D). Only three dose-dependent genetic
interactions are seen above DS R j2.6j in the WT data set,
suggesting that our method identifies few false positives. We
analyzed the distribution of S scores for WT-TOR2 and AS-
TOR2 at 1 mM BEZ235 (Figure 2E). Based on previous E-MAP
data sets, our expectation was that WT-TOR2 would show char-
acteristic single-mutant phenotypes with S scores at or near
zero. This phenotype should persist at all drug doses if
BEZ235 is selective for AS-TOR2. At the highest dose of
BEZ235, we observe a clear direct relationship between the S
score andDS in cells containing AS-TOR2. In contrast, the distri-
bution observed when 1 mM BEZ235 is applied to the WT-TOR2
is clustered around zero, as expected. Although the S score is a
useful reference for quantification, it does not report on dose-
dependent interactions, nor does it allow filtering of genetic inter-
actions that are not due to changes in the catalytic activity of
TOR. By relying on DS, we are able to selectively capture
dose-dependent interactions.
Few dose-dependent interactions were observed in crosses
with rapamycin- or BEZ235-resistant alleles. The interactions
observed were due to allelic effects from the resistance marker.
The rr-TOR1 showed no dose-dependent genetic interactions
upon drug treatment. With the rr-TOR2 allele, seven genes
(YPL150W,CKA2,BRE1, YPT7, IPK1,OPI11, and THP3) showed
chemical-genetic interactions above threshold. Dose-depen-
dent interactions with the rr-TOR2 allele arose from rapamycin
inhibition of WT-TOR1 in TORC1. These results are consistent
with our in vitro data indicating that TOR1 is the primary kinase
responsible for the outputs of TORC1.
We identified 226 dose-dependent ChE-MAP interactions
with rapamycin and BEZ235 treatment at our cutoff of DS R
j2.6j. We observed 103 rapamycin-specific dose-dependent
interactions and 123 TORC2-specific interactions, with an over-
lap of ten genes that showed a dose-dependent effect with both
(Figures 2F and S3). Eight of these shared interactions showed a
dose-dependent effect that was the same whether TORC1 or
TORC2 was inhibited (Figure 2G). We infer that the positive
interactions that arise are due to a shared function of both
complexes. The four negative interactions were compensatory
with both TORC2 and TORC1. Two genes (RAV1 and TMA23)
showed positive interactions (DS > 2.6) with TORC2 and nega-
tive interactions (DS < 2.6) with TORC1.
When we relaxed our cutoff to DS R j2.0j, we identified
eight additional dose-dependent interactions that were common
to both the rapamycin and BEZ235 data sets (Figure 2G and S3).
Six genes (MED1, BMH2, RPL37A, JJJ1, SPC2, and YLR184W)
showed positive interactions with TORC2 and negative inter-
actions with TORC1. Two genes (MKK2 and YNL217W) were
negative with TORC2 and positive with TORC1. The network1730 Cell Reports 5, 1725–1736, December 26, 2013 ª2013 The Autview provides a full account of dose-dependent interactions
observed with each TOR complex.
Several genes that interact with both TORC1 and TORC2
play important roles in ribosomal maturation. Our results show
strong positive interactions with KNS1, LHP1, and SRP40, all
of which participate in tRNA processing and ribosome matura-
tion (Figure 2G), suggesting an important role for both TORC1
and TORC2 in these processes. Although the role of TORC1
in phosphorylation of ribosomal protein S6 (RPS6) via S6-kinase
(S6K) is known (Feldman et al., 2009; Richardson et al., 2004;
Urban et al., 2007), the involvement of TORC2 was not appreci-
ated until recently (Zinzalla et al., 2011). Our data support a
role of TORC2 in ribosome biogenesis, since two genes
(TMA23 and JJJ1) involved in ribosome biogenesis (Fleischer
et al., 2006; Meyer et al., 2007) and a ribosomal protein
(RPL37A) show strong positive interactions with TORC2 while
simultaneously showing strong negative interactions with
TORC1 (Figure 2G). This indicates that these genes are in
a pathway with TORC2 and provides additional evidence that
ribosomal biogenesis plays a role in regulating TORC2 (Zinzalla
et al., 2011).
Enrichment of Sphingolipid Biosynthesis in TORC2
ChE-MAP Hits
Next, we looked in our data sets for well-characterized signaling
pathways downstream of TORC2. The sphingolipid biosynthesis
pathway is the best-characterized pathway under the control
of TORC2 (Aronova et al., 2008; Beeler et al., 1998; Tabuchi
et al., 2006). TORC2 is known to directly phosphorylate and
regulate Ypk1/2 (Aronova et al., 2008; Kamada et al., 2005; Niles
et al., 2012), and Ypk1/2 in turn phosphorylates and inactivates
Orm1 and Orm2, which negatively regulate sphingolipid bio-
synthesis (Breslow et al., 2010; Niles et al., 2012; Roelants
et al., 2011; Sun et al., 2012). We found extensive evidence indi-
cating that genes involved in sphingolipid biosynthesis interact
positively with the kinase activity of TORC2 (Figure 3A).
The dose-dependent chemical-genetic interactions between
TORC2 and sphingolipid biosynthesis serve as a biological
benchmark for the ChE-MAP technique. We observed strong
dose-dependent chemical-genetic interactions between
TORC2 and ORM2 (+3.4), DPL1 (+3.9), LCB4 (+4.2), and ISC1
(+4.4), all of which play integral roles in the pathway (Figure 3A).
No interaction was observed with TORC1, in good agreement
with prior findings (Roelants et al., 2011; Sun et al., 2012).
To confirm this phenotype, we performed tetrad analysis with
these mutants and subjected crosses corresponding to the
ChE-MAP results to increasing concentrations of rapamycin
and BEZ in a spot dilution assay (Figure 3B). The results show
that ORM2 shows a positive phenotype upon TORC2 inhibition.
The positive genetic interactions with several members of the
sphingolipid biosynthesis pathway validate ChE-MAP as a viable
strategy for identifying downstream signaling pathways.
Cellular Compartment and Process Enrichment of
TORC2 Interactions
Using the ChE-MAP interaction data, we asked whether there
was functional enrichment for genes annotated in a particular
cellular compartment or biological process. Our results werehors
A B
DC
AS-
AS-
AS-AS-
AS-
WT-
WT-
WT-
Figure 3. Enrichment in Biological Processes
(A) The sphingolipid biosynthesis pathway shows consistent dose-dependent behavior across all members of the pathway that were included in the screen, in
good agreement with theoretical prediction. S score is indicated on a color metric scale, with blue indicating a strongly negative interaction and yellow indicating a
strongly positive interaction.
(B) Genotyped and sequenced members of pulled tetrads grown on plates containing increasing concentrations of rapamycin or BEZ235 confirm phenotypes
tested using the ChE-MAP.
(C) Bar graph shows the fraction of each functional biological category that was included in the E-MAP.
(B) Enrichment in either of the two data sets above or belowDS = 2.0 was calculated using Fisher’s exact test to identify terms in the cellular process GO Slim that
were significantly enriched. Significant p values are highlighted in yellow.
See also Figure S3.not biased, because we included a diverse and balanced collec-
tion of queries in the ChE-MAP (Figure 3C).
TORC2-interacting genes analyzed for enrichment in a cellular
compartment using Gene Ontology (GO) (Berriz et al., 2009)
terms show a 2-fold enrichment for proteins that localize to the
endoplasmic reticulum (ER; p < 0.05), controlling for sampling
bias in the gene-deletion library used for this study. This result
is consistent with recent work showing that mTORC2 cofraction-
ates with the ER (Boulbe´s et al., 2011), and suggests that the
localization of TORC2 is conserved. This expands our under-
standing of previous work showing that TORC2 in S. cerevisiae
localizes to the plasma membrane and regulates sphingolipid
biosynthesis (Berchtold and Walther, 2009; Berchtold et al.,
2012). TORC1, by contrast, localizes in the vacuole of
S. cerevisiae and to the lysosome surface in mammalian cells
(Berchtold and Walther, 2009; Loewith et al., 2002; Zoncu
et al., 2011).
Next, we analyzed the TORC1 and TORC2 data sets for
enrichment of hits mapping to specific biological processes
(Berriz et al., 2009). Whereas no significant enrichment was
observed with TORC1 hits, significant enrichment was observed
for positive hits with TORC2. The ChE-MAP showed significant
enrichment (p < 0.05) for ‘‘generation of precursor metabolitesCell Reand energy’’ for positively interacting TORC2 hits. Although
TOR has been loosely associated with energy homeostasis
due to the obvious energetic demands of protein synthesis and
ribosome biogenesis, a link with metabolite synthesis was not
previously shown. To investigate this further, we sought to
integrate published physical interaction data with our chemi-
cal-genetic results to see whether specific metabolic processes
have predominantly positive interactions with TORC2.
Integrated Functional Network of TOR Signaling
To look for proteins involved in metabolite synthesis that physi-
cally interact with TOR, we searched for genes in metabolic
GO terms that had large numbers of physical interactions with
members of the TOR signaling pathway. We found that many
proteins in the PPP have physical interactions with proteins in
the TOR signaling pathway, which compelled us to construct a
comprehensive network of PPP proteins that physically interact
with each of the TOR complexes.
The network of genes that are annotated (by GO terms) to the
PPP shows a distinct signature with TORC1 genes compared
with TORC2 genes, as shown in Figure 4A. The figure shows
that many enzymes that catalyze steps in the PPP physically
interact with proteins that positively interact with AS-TOR2ports 5, 1725–1736, December 26, 2013 ª2013 The Authors 1731
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Figure 4. Effect of Rapamycin and BEZ235 on Metabolites in the PPP
(A) Network of ChE-MAP hits that have physical interactions with genes within the PPP GO term. Rounded rectangles and blue edges indicate chemical-genetic
interactions and are colored according to the DS score for the indicated gene. Enrichment for PPP-linked genes that positively interact with TORC2 is 2-fold
higher than expected by random chance, with p = 0.02. Black nodes indicate genes not found in our data set (http://thebiogrid.org) or in previous studies (Fan
et al., 2008; Fasolo et al., 2011; Graille et al., 2005; Hesselberth et al., 2006; Krogan et al., 2006; Ptacek et al., 2005; Yu et al., 2008). Black edges indicate a
physical interaction.
(B) 6PG levels were quantified by LC/MS over a 60 min time course in which cells were perturbed by nitrogen starvation, inhibited with rapamycin (WT-TOR2), or
inhibited with BEZ235 or rapamycin (AS-TOR2).
(C) R5P levels were quantified by LC/MS over a 60 min time course in which cells were perturbed by nitrogen starvation, inhibited with rapamycin (WT-TOR2), or
inhibited with BEZ235 or rapamycin (AS-TOR2).
(D) Isotope-labeled 6PG allows direct measurement of newly synthesized metabolite in AS-TOR2 and WT-TOR2 cells, and quantification of oxPPP flux.
Treatment with BEZ235 shows a significant change (**) after the short 30 min time point.
In (B)–(D), error bars represent SD from the mean calculated from two independent biological replicates. See also Figure S4 and Table S4.(BDF2, GAC1, URN1, and YPL150W). In contrast, enzymes in
the PPP generally show physical interactions with proteins that
negatively interact with TORC1 (TPM1, SET2, and HAT2). The
network shows a >2-fold enrichment of positive interactions
with TORC2 above what would be expected by chance alone
(p = 0.02) and predominantly negative interactions with TORC1
(p = not significant), suggesting that the PPP is in a linear
pathway with TORC2 and in either a noninteracting or parallel
pathway with TORC1. This phenotype is the hallmark of a
TORC2-regulated pathway, and thus we were motivated to
investigate whether metabolite levels and particularly the PPP
are regulated by TORC2.
Metabolomic Analysis of TORC1 and AS-TOR2
To test the role of TORC2 in the PPP,we used reverse-phase ion-
paired liquid chromatography/mass spectrometry (LC/MS) to
monitor drug-dependent changes in more than 130 cellular
metabolites, including constituents of the PPP pathway (Fig-
ure S4). Rapid metabolic changes that take place soon after
drug treatment suggest direct regulation of metabolic enzymes,1732 Cell Reports 5, 1725–1736, December 26, 2013 ª2013 The Autwhereas changes that occur on the timescale of yeast cell repli-
cation/division aremore likely to indicate transcriptional changes
to metabolic enzymes.
As an internal quantitative and qualitative reference for the
magnitude of the metabolic changes, and a point of comparison
for our drug treatment, we also assessedmetabolic changes due
to nitrogen starvation. Nitrogen starvation is akin to rapamycin
treatment in that it disrupts the phosphorylation of TORC1
substrates (Urban et al., 2007). To identify changes in metabolite
levels in response to inhibition of the TOR kinase, we treated
cells with inhibitors or switched them to low-nitrogen media.
We then quantified the metabolic changes over time by LC/MS
to look for inhibitor-dependent changes in soluble metabolite
levels.
Inhibition of TORC1 or TORC2 led to changes across all
aspects of metabolism. We filtered the metabolic results to
capture the change in response upon drug inhibition over the
60 min time course. After 1 hr of drug treatment, above a
threshold of log(metabolite)R j1.5j, nitrogen starvation showed
changes in 18 metabolites out of 128 measured, rapamycinhors
showed changes in 24 metabolites out of 128 measured, and
TORC2 treatment affected 19 out of 114 metabolites measured.
We observed that metabolic intermediates involved in the PPP
were strongly downregulated in response to AS-TOR2 inhibition.
In our experiments, 6-phospho-D-gluconate (6PG) and ribose-5-
phosphate (R5P), two intermediates that are specific to the PPP,
showed a rapid time-dependent response to treatment with
BEZ235 (Figures 4B and 4C), and a slower and more modest
response to rapamycin. R5P is the product of the oxidative
PPP (oxPPP) and was recently shown to be produced by ribo-
neogenesis (Clasquin et al., 2011). Although this metabolite
was perturbed by the AS-TOR2 allele, the metabolite showed
an additional time-dependent decrease in levels after 7 min of
treatment with BEZ235. These changes may suggest a role for
TORC2 in regulating both the oxidative and nonoxidative
branches of the PPP.
In contrast, the delayed downregulation in response to TORC1
inhibition is consistent with previously proposed models that
put enzymes in the PPP under the control of transcription factors
downstream of TORC1 (Du¨vel et al., 2010; Robitaille et al., 2013).
The rapid response upon BEZ235 treatment indicates that
TORC2 may have more direct control over the PPP through
kinase signaling. This hypothesis is supported by a GO analysis
of the ChE-MAP (Figure 4A) that showed that seven proteins
with chemical-genetic interactions with TORC2 are annotated
to physically interact with metabolic enzymes of the PPP. All
of these are positive interactions, indicating they are in a linear
pathway with TORC2. Strong positive interactors with TORC2
include BDF2 and GAC1, which both physically interact with
the tRNA export protein Sol1, a close homolog of Sol3/Sol4,
which catalyzes the second step of the PPP, leading to the gen-
eration of 6PG. Strong interactions are also observed between
TORC2 andRBL2, which physically interacts with Rki1. Rki1 reg-
ulates the third step in the PPP, leading to the production R5P.
To test whether TORC2 was influencing metabolite levels in
the PPP by direct regulation of metabolic flux, we undertook
an analysis using the tracer 1,2-13C-glucose to quantify the
levels of 6PG and R5P, and to measure the relative ratio of the
oxPPP and nonoxidative PPP (non-oxPPP) transketolase reac-
tion. The rapid decrease of 6PG in the AS-TOR2 strain upon
BEZ235 addition (Figure 4D) confirms TORC2’s posttranslational
regulation of the oxPPP, since the change in metabolite levels
occurred on a rapid timescale (<30 min) as we observed previ-
ously. The lack of a substantial change of oxPPP flux in the
AS-TOR2 strain relative to WT (Figure S4) upon BEZ235 treat-
ment suggests that TORC2 does not differentially regulate
oxPPP and non-oxPPP. However, it may regulate the PPP up-
stream of the split between oxPPP and non-oxPPP, likely
through differential regulation of glucose-6-phosphate dehydro-
genase (the reaction upstream of 6-phosphogluconate) and 6-
phosphogluconate dehydrogenase.
Conclusions
Yeast screens remain the most versatile tool for assessing func-
tional genomic interactions at the organismal level. Genetic
knockouts are facile for nonessential genes, but other methods
are required for queries of essential genes such as the TOR2
kinase. Among these, decreased abundance by mRNA pertur-Cell Rebation (DAmP), temperature-sensitive (TS) degrons designed
to rapidly degrade proteins at the restrictive temperature, and
chemical inhibitors for a specific target are the most commonly
employed techniques. The use of DAmP alleles can be unreliable
due to variable levels of knockdown. TS strategies are effective
but can suffer from pleiotropy. In particular, several different
TS-TOR2 isolates have been reported to have widely varying
effects on cell cycle, budding, and actin structures at the restric-
tive temperature (Helliwell et al., 1998a). Chemical inhibitors are
fast acting, but the number of interesting essential targets far
exceeds the number of chemical tools available to inhibit them.
In this study, we created a chemical-genetic tool that is highly
specific and allows rapid inactivation of the TORC2 kinase.
We used this tool to systematically and quantitatively probe
the genetic interaction landscape of TORC2 kinase activity
in vivo. Our method reports precisely on kinase activity and
avoids the plethora of interactions that arise from destruction
of protein-protein interactions.
We confirmed the robustness of our technique through
positive identification of the sphingolipid biosynthesis pathway
downstream of TORC2, and showed a significant enrichment
in functional connections with proteins localized to the ER.
Data showing enrichment for ‘‘generation of metabolites and
energy’’ directed us to investigate the PPP with physical inter-
action networks that showed a pattern of interactions that is
consistent with the PPP existing in a linear pathway with
TORC2. By studying metabolite levels with AS-TOR2 in the pres-
ence of BEZ, we were able to observe large and rapid (<30 min)
changes in metabolites that are created in the PPP, and further
showed that these changes necessarily occur upstream of the
transketolase reaction, since the data do not suggest a differen-
tial flux through the non-oxPPP and oxPPP.
The suggestion of a role for TORC2 in ribosomal biogenesis
(Figure 2E) has interesting implications for how the cell balances
energy demands to meet these needs. Emerging evidence
indicates that TORC2 is an important node in ribosome biogen-
esis (Zinzalla et al., 2011). The high energy requirements of ribo-
some biogenesis create a high demand for ribose relative to
NADPH, leading to activation of the PPP and production of
R5P (Clasquin et al., 2011). Our evidence shows that TORC2
positively regulates metabolite synthesis in the PPP (Figure 4D)
and may act as a critical relay between ribosome biogenesis
and the PPP. This is particularly compelling in conjunction with
evidence showing that upregulation of the non-oxPPP is
required for tumor survival (Deberardinis et al., 2008).
Our approach represents a unique union of genetics and
pharmacology that facilitates rapid assessment of gene-selec-
tive effects that could act as a first line of evidence in the search
for synergistic therapeutics. It allows for amore granular analysis
of functional genetic interactions that refer specifically to the
catalytic activity of the kinase rather than to the scaffolding roles
of the Tor protein. These findings will be a valuable resource for
deciphering the different physiological functions of TORC1 and
TORC2 in yeast. Such an understanding in turnmay help to eluci-
date the roles these complexes play in mammals, where this
approach cannot be directly applied, and thereby aid in the
design of combination therapy regimens involving TOR
inhibitors.ports 5, 1725–1736, December 26, 2013 ª2013 The Authors 1733
EXPERIMENTAL PROCEDURES
Generation of Point Mutants
The C-terminal region TOR1 or TOR2 (including the FAT, FRB, kinase domain,
and 160 bp of the 30 UTR) was cloned onto plasmid pFA6-NAT-MX6, into the
multiple cloning site immediately preceding the NAT gene (which confers
resistance to nourseothricin; Werner Bioagents). AS-TOR2 (L2178A), rr-TOR2
(S1975I), and rr-TOR1 (S1972I) mutants were generated using site-directed
mutagenesis. These mutants were amplified using PCR and transformed
into the BY4742 strain, in which the C-terminal region of either TOR1 or
TOR2 had been displaced by k.l URA3. Following selection on NAT and 5-
FOA, the mutants were sequenced to confirm insertion of the desired muta-
tions. Subsequently, the diploid mutant strains were sporulated, the Mata
haploid strains were selected by replica plating on selective media, and the
presence of the mutation was again confirmed by sequencing.E-MAP Experiments
Strain construction, plating of mutants, mutant selection, and scoring of
genetic interactions (S scores) were performed as previously described
(Collins et al., 2006; Schuldiner et al., 2005). Using a Singer Instruments
pinning robot, haploid double mutants were simultaneously grown in 1,536-
well format at 30C on agar plates containing DMSO or a selective TOR inhib-
itor. Mutants in this study were screened in tandem with a large number of
queries (Table S4) to ensure robust statistics for averaging (n > 30). Several
unrelated queries, strains containing point mutants to SCH9, WT strains con-
taining a TOR1 marker, and a TS-TOR2 allele were used as query strains. In
addition to the standard media containing G418 and NAT, plates used in the
screen contained either DMSO, 0.25 mM BEZ235, 1.00 mM BEZ235, 10 nM
rapamycin, or 100 nM rapamycin. The plates were photographed and the
area of each colony was converted into pixels to quantitatively assess colony
size. In untreated or treated conditions, colony sizes were based on three repli-
cate measurements. For a given double mutant, the experimental data were
used to assign a quantitative S score based on amodified t test that compares
the observed double-mutant growth rate with an expected growth rate based
on the average colony size across an entire plate.Dose-Dependent Interaction Scoring System
Dose-dependent genetic interactions were identified for a given gene by
searching for a series of S scores for that gene that showed a directional shift
that correlated with drug concentration. The magnitude of the interaction was
evaluated as the difference between the high-dose and the corresponding
control strain (DS = S scorehighdrug – S scoreDMSO; DS scoresR j2.6j).Cellular-Compartment Enrichment of TORC2 Dose-Dependent
Interactions
Enrichment of TORC2 Dose-Dependent Interactions
Genes with a dose-dependent interaction (DSR j2.0j) were tested for enrich-
ment in a specific cellular compartment. Fisher’s exact test (Berriz et al., 2009)
was used to identify terms in the cellular compartment GO Slim that were
significantly enriched in dose-dependent hits, resulting in the observation
that dose-dependent hits are 1.6 times more likely to be localized to the
ER than expected (p < 0.05 after correcting for multiple testing). The back-
ground for this calculation was all mutants with measured scores from the
AS-TOR2 + BEZ235 screen, and consequently the observed enrichment is
not due to the bias on the array or to data-quality filtering. The same approach
was used to identify terms in the Biological Process Ontology that showed
significant enrichment for dose-dependent hits. All process terms having
1.5-fold or better enrichment are shown in Figure 3.Tetrad Analysis
WT-TOR2 and AS-TOR2 were mated to a single-deletion strain of interest for
48 hr prior to sporulation at room temperature for 3–5 days. The ascus was di-
gested with zymolyase for 20 min prior to tetrad dissection. The tetrads were
replica plated on selective media for genotyping, and all strains were verified
using check PCR and sequencing of the TOR kinase domain locus.1734 Cell Reports 5, 1725–1736, December 26, 2013 ª2013 The AutSpot Test Assay
Overnight cultures were grown to saturation, diluted to OD600 = 0.2, and grown
until all four strains had OD600 = 0.8. Two-fold serial dilutions of cells were
plated on DMSO; 0.1 mM, 0.25 mM, or 1 mM BEZ235; or 10 nM, 50 nM, or
100 nM rapamycin. Plates were grown at 30C and imaged after 24 hr.GO Network Analysis
Circular nodes were created for all genes within a given GO term. Rectangular
nodes correspond to hits in either the rapamycin or BEZ235 data sets, and cir-
cular nodes are physical binding interactions reported in the literature (Stark
et al., 2006) that are absent in our screen. Genetic interactions between
TORC1 or AS-TOR2 were computed and illustrated using blue edges.Metabolite Measurement
The metabolome of S. cerevisiae was characterized as described previously
(Xu et al., 2012). Saturated overnight cultures were diluted 1:30 and grown in
liquid media in a shaking flask to A600 of 0.6. A portion of the cells (3 ml)
were filtered onto a 50 mm nylon membrane filter, which was immediately
transferred into 20C extraction solvent (40:40:20 acetonitrile/methanol/
water). Serial extraction was then carried out at the indicated time points after
drug treatment. Cell extracts were analyzed by reverse-phase ion-pairing LC
coupled by negative-mode electrospray ionization (ESI) to a high-resolution,
high-accuracy mass spectrometer (Exactive; Thermo Fisher Scientific) oper-
ated in full scan mode at 1 s scan time, 105 resolution. Compound identities
were verified by exact mass and retention time matched to an authenticated
standard (Melamud et al., 2010). Isomers are reported separately only when
they were fully chromatographically resolved.Metabolic Flux Measurement
Yeast cells were grown in 1,2-13C2-glucose in the presence of 1 nM or 5 nM
estradiol. The use of 1,2-13C-glucose allows measurement of oxPPP flux. All
of the isotope-labeled forms of ribose phosphate are quantitated. The flux is
calculated as follows: oxPPP flux = (f1 + f2)/(f3 + f4  f0), in which fn is the
labeling fraction of the n-labeled ribose phosphate. The oxidative branch of
the PPP yields 1- and 3-labeled pentose phosphate. The nonoxidative branch
of the PPP yields 2- and 4-labeled pentose phosphate. One molecule of
0-labeled pentose phosphate is generated for every 2- or 4-labeled pentose
phosphate produced through erythrose phosphate. Therefore, 0-labeled
pentose phosphate is subtracted to reflect the true flux of non-oxPPP.SUPPLEMENTAL INFORMATION
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